Clinical trial · Interventional
Modulation of Ciliogenesis in Glioma Stem Cells
Control of Growth and Invasiveness of Glioblastoma by Modulation of Ciliogenesis in Glioma Stem Cells. A Novel Target Against Glioblastoma for Precision Medicine. RF-2019-12368786
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims at investigating the cilium-related transcriptome in patients-derived glioblastoma stem cells and the potential impact of modulation of cilium players in vitro, in vivo and ex vivo in glioblastoma brain organoids. Moreover, drugs inhibiting cilia disassembly will be tested. Finally, the potential prognostic role of a cilium-related gene expression signature in glioblastoma will be assessed.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Glioblastoma | Glioblastoma | CURATED_BROADER | 0.80 |
| Glioma, Malignant | Malignant Glioma | ALIAS | 0.90 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Biological sample collection | Other | — | UNRESOLVED |
| Dissecting ciliogenesis players | Other | — | UNRESOLVED |
| Validating ciliogenesis players | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Biological sample collection
- description
- Collection of tumor tissue and PBMC for the generation of glioblastoma stem cell cultures and brain organoids.
- interventionNames
- Other: Biological sample collection
- Other: Dissecting ciliogenesis players
- Diagnostic Test: Validating ciliogenesis players
Primary outcomes (1)
- measure
- Biological
- timeFrame
- Through study completion, an average of 2 years
- description
- Correlation between modulation of cilia disassembly complex genes, and tumor growth and invasion in brain organoids.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: To be enrolled in the study patients must: 1. Have a radiological diagnosis of supratentorial glioblastoma, or 2. Have a radiological diagnosis of first recurrence of a primary supratentorial glioblastoma (for which a formal histopathologic diagnosis of glioblastoma had been made at first surgery), according with RANO criteria (Wen, 2010); 3. Be a candidate to neurosurgery for glioblastoma at the Operational Unit of Neurosurgery FPG; 4. Be of an age of 18 years or above; 5. Provide written informed consent for participation to the study. Exclusion criteria To be enrolled in the study patients must not: 1. Have not enough pathological material removed at surgery available both for mandatory routine histopathological diagnosis and for the present study, as judged by the Principal Investigator; 2. Have not a definitive pathological diagnosis of a primary supratentorial GBM, according with 2016 WHO classification.
References
Publications (0)
Data not yet available